Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Everolimus
Drug ID BADD_D00858
Description Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Indications and Usage Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole. Indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or metastatic disease. Indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. Indicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. Indicated in pediatric and adult patients with tuberous sclerosis complex (TSC) for the treatment of subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.
Marketing Status approved
ATC Code L01EG02; L04AA18
DrugBank ID DB01590
KEGG ID D02714
MeSH ID D000068338
PubChem ID 6442177
TTD Drug ID D0K3QS
NDC Product Code 52076-6247; 62227-019; 68254-6234; 71052-559; 49884-283; 0054-0480; 0078-0566; 0078-0620; 0078-0627; 0378-3096; 0378-3097; 67877-721; 0054-0472; 70377-012; 65129-1324; 71796-012; 0078-0422; 0093-7767; 0093-7768; 49884-119; 51991-821; 63850-0062; 63850-0064; 70377-010; 70377-011; 63850-0059; 67877-718; 0054-0470; 17404-1027; 65727-064; 0078-0567; 51991-824; 63850-0058; 0378-0007; 0378-3098; 0054-0497; 65727-063; 0078-0594; 0078-0628; 49884-158; 0378-0005; 0378-3099; 67877-720; 0054-0471; 52076-6253; 62227-013; 70225-1103; 0078-0415; 0078-0417; 0078-0626; 0054-0482; 52076-6234; 63850-0063; 67877-719; 63850-0061; 0054-0481; 0054-0604; 49884-160; 51991-822; 63850-0060; 0378-0006; 70377-013; 65727-046; 0078-0414; 0093-7766; 49884-125; 49884-127; 49884-128; 49884-159; 51991-823
UNII 9HW64Q8G6G
Synonyms Everolimus | SDZ RAD | RAD, SDZ | SDZ-RAD | 40-O-(2-hydroxyethyl)-rapamycin | RAD 001 | 001, RAD | RAD001 | Certican | Afinitor
Chemical Information
Molecular Formula C53H83NO14
CAS Registry Number 159351-69-6
SMILES CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O) C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Ill-defined disorder08.01.03.049--Not Available
Sensation of foreign body08.01.09.0020.000749%Not Available
Ulcer haemorrhage08.03.06.003; 24.07.01.0400.000153%Not Available
Blood disorder01.05.01.0040.000382%Not Available
Immunodeficiency10.03.02.0020.000489%Not Available
Adverse drug reaction08.06.01.009--Not Available
Bone lesion15.02.04.0160.001422%Not Available
Bone marrow disorder01.05.01.0060.000413%Not Available
Disease progression08.01.03.0380.035011%
Diverticular perforation07.04.04.0080.000153%Not Available
Drug intolerance08.06.01.013--Not Available
Neoplasm recurrence16.16.02.0040.000489%Not Available
Obstructive airways disorder22.03.01.0110.000795%Not Available
Pulmonary toxicity22.01.02.007; 12.03.01.0130.001483%Not Available
Food intolerance14.02.01.0050.000336%Not Available
Hepatic lesion09.01.08.0050.002018%Not Available
Hepatobiliary disease09.01.08.003--Not Available
Immunosuppression10.03.02.0010.000382%Not Available
Lung neoplasm22.08.01.006; 16.19.04.0010.000382%Not Available
Lymphocytic infiltration01.02.01.0120.000153%Not Available
Hyperlipidaemia14.08.03.0010.002507%
Pigmentation disorder23.05.03.0010.000489%Not Available
Renal mass20.01.02.0070.000153%Not Available
Metastasis16.22.01.0010.002553%Not Available
Renal impairment20.01.03.0100.004418%Not Available
Sinus disorder22.04.06.0020.000933%
Respiratory tract infection22.07.07.001; 11.01.08.017--Not Available
Non-cardiac chest pain22.12.02.009; 08.01.08.0060.000153%
Hepatic enzyme abnormal13.03.04.026--Not Available
Hyperamylasaemia14.11.01.0030.000153%Not Available
The 26th Page    First    Pre   26 27 28 29 30    Next   Last    Total 32 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene